On-Demand Bioresorbable OptoElectronic System for In-Vivo and In-Situ Monitoring of Chemotherapeutic Drugs

Develop a bioresorbable chemical sensing system for real-time monitoring of doxorubicin in-vivo, enhancing personalized cancer treatment while eliminating the need for device retrieval surgery.

Subsidie
€ 2.606.250
2022

Projectdetails

Introduction

We envision a radically new technology for in-vivo bioresorbable chemical sensing, where optical devices, power and light sources, synthetic receptors - made out of materials that completely dissolve with biologically benign byproducts in biofluids - will be developed and integrated together.

System Design

The sensing system, the size of 1 EuroCent, will be coated by a long-lived biocompatible polymer designed with on-demand degradation. It will then be implanted in the body to monitor in-vivo, in-situ, and in real-time a chemotherapeutic drug, doxorubicin, commonly used to treat cancer.

Dissolution Process

The system is then fully and safely RESORBed once no longer needed using an external temperature-trigger that initiates the dissolution of the protecting coating and, in turn, of the system. This process avoids device-retrieval surgery that may cause tissue lesion/infection.

Objectives

The general objective is to demonstrate:

  1. Fabrication
  2. Operation (2 months) in-vivo and in real-time
  3. Dissolution of such a bioresorbable chemical sensing system for the detection of doxorubicin in an animal model.

This will break new ground in in-situ monitoring of chemotherapeutic drugs, enabling for the first time a fine-tuning of the drug dose at the tumor site, thereby increasing patient survival rates.

Risk Management

Being aware of the project risks, we have broken down the general objectives into different specific objectives. We have identified a set of Key Performance Indicators, alternative material synthesis/device fabrication techniques, and mitigation measures to tackle major risks.

Future Implications

The RESORB technology truly represents the foundation of a future technology for personalized medicine. It enables addressing a number of medical issues for which continuous and localized monitoring of specific analytes (i.e., biomarkers and drugs) in-vivo for a prescribed time is of chief importance.

Examples of Applications

Examples include:

  • Acute trauma treatment
  • Post-surgery sepsis
  • Drug therapeutic profiling

These are all cases for which ex-situ analysis of biofluids has proved to be not fully adequate for clinical needs.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.606.250
Totale projectbegroting€ 2.606.250

Tijdlijn

Startdatum1-4-2022
Einddatum30-9-2025
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • UNIVERSITA DI PISApenvoerder
  • INSTITUT MINES-TELECOM
  • UNIVERSITA DEL SALENTO
  • INSTITUTO DE TELECOMUNICACOES
  • UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA
  • UNIVERSITY COLLEGE LONDON
  • LIBERA UNIVERSITA DI BOLZANO

Land(en)

ItalyFrancePortugalUnited Kingdom

Vergelijkbare projecten binnen EIC Pathfinder

EIC Pathfinder

Bioorthogonal Implantable Iontronic Switch to Temporally Control the Local Release of Chemotherapeutics

The project aims to develop an implantable bioSWITCH for on-demand drug delivery to tumors, enhancing treatment efficacy and survival rates in pancreatic cancer.

€ 4.420.511
EIC Pathfinder

In-vessel implantable smart sensing device for personalised medicine

The IV-Lab project develops a miniaturized implantable sensor for continuous health monitoring in cardiovascular patients, enabling personalized medical interventions and reducing hospitalizations.

€ 4.158.610
EIC Pathfinder

Personalised Adaptive Medicine

The PERAMEDIC project aims to develop a desktop-sized system for personalized polypill formulation using 3D printing and precise dosing to enhance treatment outcomes and patient adherence.

€ 1.726.876
EIC Pathfinder

ISOS-Implantable Ecosystems of Genetically Modified Bacteria for the Personalized Treatment of Patients with Chronic Diseases

ISOS aims to create a personalized bioreactor using engineered probiotics for on-demand delivery of therapeutic compounds to treat chronic diseases like age-related macular degeneration.

€ 2.433.300
EIC Pathfinder

Live Cell Spectroscopy Analysis for Personalised Particle Radiation Therapy of Metastatic Bone Cancer

BoneOscopy aims to revolutionize metastatic bone cancer treatment by enabling daily monitoring during particle radiotherapy, enhancing personalized care and treatment efficacy.

€ 3.069.321

Vergelijkbare projecten uit andere regelingen

ERC Starting...

Implantable sensors and ultrasonic data link with triggered bioresorption for next-gen wireless cardiac monitoring

The 2ND-CHANCE project aims to develop bioresorbable implants for continuous cardiac monitoring post-surgery, reducing rehospitalization risks and eliminating the need for removal surgery.

€ 2.500.000
ERC Proof of...

Biomimetic Sensorized Barriers-on-a-Chip: Unveiling a new Generation of Market-Ready Investigation Tools

This project aims to validate a novel, dynamic blood-brain barrier model with sensing features for improved drug screening in CNS pathologies, reducing reliance on animal testing and clinical trial failures.

€ 150.000
ERC Starting...

Bioorthogonal Iontronic Chemistry: Spatiotemporal Drug Release with Electronic Precision

Develop a programmable drug delivery system using Biontronic Chemistry for precise spatiotemporal release, enhancing treatment efficacy while minimizing side effects in various therapies.

€ 1.496.795
ERC Starting...

Multifunctional Platform Technology for Magnetically Actuated Controlled Drug Release from Biodegradable Scaffolds

MAD Control aims to develop a multifunctional platform for biodegradable cardiovascular scaffolds that enables precise, on-demand drug release through real-time imaging and magnetic actuation.

€ 1.495.288
ERC Starting...

Neuromorphic Flexible Electro/chemical Interface for in-Memory Bio-Sensing and Computing.

Develop a miniaturized, self-contained biosensing technology using neuromorphic devices for real-time monitoring and classification of neurodegenerative biomarkers in individualized healthcare.

€ 1.500.000